Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol

被引：0
|
作者：
Ditte Hansen
Lisbet Brandi
Knud Rasmussen
机构：
[1] Roskilde Hospital,Medical Department
[2] University of Copenhagen,Department of Surgery and Internal Medicine
来源：
BMC Nephrology | / 10卷
关键词：
Chronic Kidney Disease; Hypercalcemia; Vascular Calcification; Secondary Hyperparathyroidism; Alfacalcidol;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients
    Kiattisunthorn, Kraiwiporn
    Wutyam, Kittikarn
    Indranoi, Artit
    Vasuvattakul, Somkiat
    NEPHROLOGY, 2011, 16 (03) : 277 - 284
  • [2] Health-Economic Comparison of Paricalcitol, Calcitriol and Alfacalcidol for the Treatment of Secondary Hyperparathyroidism during Haemodialysis
    Hubertus Rosery
    Rito Bergemann
    Steven E. Marx
    Axel Boehnke
    Joel Melnick
    Raimund Sterz
    Laura Williams
    Clinical Drug Investigation, 2006, 26 : 629 - 638
  • [3] Health-economic comparison of paricalcitol, calcitriol and Alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis
    Fiedler, Roman
    CLINICAL DRUG INVESTIGATION, 2007, 27 (12) : 865 - 866
  • [4] Health-Economic Comparison of Paricalcitol, Calcitriol and Alfacalcidol for the Treatment of Secondary Hyperparathyroidism during Haemodialysis
    Roman Fiedler
    Clinical Drug Investigation, 2007, 27 : 865 - 866
  • [5] No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial
    Hansen, Ditte
    Rasmussen, Knud
    Danielsen, Henning
    Meyer-Hofmann, Helmut
    Bacevicius, Egidijus
    Lauridsen, Thomas G.
    Madsen, Jens K.
    Tougaard, Birgitte G.
    Marckmann, Peter
    Thye-Roenn, Peter
    Nielsen, Jorgen E.
    Kreiner, Svend
    Brandi, Lisbet
    KIDNEY INTERNATIONAL, 2011, 80 (08) : 841 - 850
  • [6] A Randomised Clinical Study of Alfacalcidol and Paricalcitol
    Hansen, Ditte
    DANISH MEDICAL JOURNAL, 2012, 59 (02):
  • [7] Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol
    Hansen, Ditte
    Rasmussen, Knud
    Pedersen, Susanne M.
    Rasmussen, Lars M.
    Brandi, Lisbet
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (06) : 2263 - 2269
  • [8] Efficacy of intravenous alfacalcidol in the treatment of secondary hyperparathyroidism in patients on hemodialysis
    Gonzalez, M. T.
    Torregrosa, J. V.
    Colome, E.
    Mendia, A.
    Pavesi, M.
    NEPHRON CLINICAL PRACTICE, 2008, 108 (02): : C141 - C147
  • [9] A randomised controlled trial to examine the effects of cinacalcet on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism
    Eddington, Helen
    Chinnadurai, Rajkumar
    Alderson, Helen
    Ibrahim, Sara T.
    Chrysochou, Constantina
    Green, Darren
    Erekosima, Ibi
    Hutchison, Alastair
    Bubtana, Abdalla
    Hegarty, Janet
    Kalra, Philip A.
    BMC NEPHROLOGY, 2021, 22 (01)
  • [10] Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism
    Sprague, SM
    Llach, F
    Amdahl, M
    Taccetta, C
    Batlle, D
    KIDNEY INTERNATIONAL, 2003, 63 (04) : 1483 - 1490
12345